Volume 25, Number 9—September 2019
Research
Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000–June 30, 2016
Table 2
Serotype rank | Serotype | Total cases | Nonmeningitis cases, n = 20,800, no. (%) | Meningitis cases, n = 920, no. (%) | aOR (95% CI) | p value† |
---|---|---|---|---|---|---|
1 | 8 | 3,285 | 3,184 (15.3) | 101 (11.0) | 0.69 (0.56–0.86) | <0.001 |
2 | 12F | 1,809 | 1,729 (8.3) | 80 (8.7) | 0.99 (0.78–1.27) | 0.961 |
3 | 22F | 1,725 | 1,640 (7.9) | 85 (9.2) | 1.39 (1.1–1.76) | 0.006 |
4 | 3 | 1,598 | 1,542 (7.4) | 56 (6.1) | 0.99 (0.74–1.31) | 0.924 |
5 | 7F | 1,542 | 1,482 (7.1) | 60 (6.5) | 0.73 (0.56–0.96) | 0.026 |
6 | 19A | 1,485 | 1,446 (7.0) | 39 (4.2) | 0.62 (0.45–0.86) | 0.005 |
7 | 15A | 1,024 | 986 (4.7) | 38 (4.1) | 1.09 (0.78–1.54) | 0.603 |
8 | 9N | 954 | 928 (4.5) | 26 (2.8) | 0.77 (0.51–1.15) | 0.2 |
9 | 33F | 827 | 774 (3.7) | 53 (5.8) | 1.34 (0.99–1.81) | 0.057 |
10 | 1 | 602 | 588 (2.8) | 14 (1.5) | 0.33 (0.19–0.56) | <0.001 |
11 | 10A | 566 | 511 (2.5) | 55 (6.0) | 2.06 (1.52–2.79) | <0.001 |
12 | 23A | 548 | 523 (2.5) | 25 (2.7) | 1.51 (1–2.29) | 0.052 |
13 | 24F | 548 | 528 (2.5) | 20 (2.2) | 0.73 (0.46–1.16) | 0.187 |
14 | 6C | 514 | 497 (2.4) | 17 (1.8) | 0.95 (0.58–1.57) | 0.852 |
15 | 11A | 512 | 498 (2.4) | 14 (1.5) | 0.71 (0.41–1.23) | 0.221 |
16 | 23B | 499 | 462 (2.2) | 37 (4.0) | 1.73 (1.21–2.48) | 0.003 |
17 | 15B/C | 453 | 416 (2.0) | 37 (4.0) | 1.31 (0.91–1.89) | 0.146 |
18 | 16F | 418 | 408 (2.0) | 10 (1.1) | 0.77 (0.41–1.45) | 0.415 |
19 | 35F | 371 | 349 (1.7) | 22 (2.4) | 1.47 (0.93–2.32) | 0.096 |
20 | 35B | 334 | 308 (1.5) | 26 (2.8) | 2.12 (1.38–3.25) | <0.001 |
21 | 31 | 282 | 273 (1.3) | 9 (1.0) | 1.14 (0.58–2.25) | 0.703 |
22 | 20 | 240 | 235 (1.1) | 5 (0.5) | 0.46 (0.19–1.12) | 0.086 |
23 | 38 | 239 | 229 (1.1) | 10 (1.1) | 0.79 (0.41–1.54) | 0.49 |
24 | 17F | 235 | 221 (1.1) | 14 (1.5) | 1.71 (0.98–2.98) | 0.058 |
25 | 19F | 183 | 171 (0.8) | 12 (1.3) | 1.24 (0.68–2.28) | 0.483 |
26 | 4 | 135 | 132 (0.6) | 3 (0.3) | 0.4 (0.13–1.28) | 0.123 |
27 | 14 | 94 | 93 (0.4) | 1 (0.1) | 0.26 (0.04–1.87) | 0.18 |
28 | 6A | 93 | 88 (0.4) | 5 (0.5) | 1.34 (0.52–3.45) | 0.538 |
29 | 6B | 90 | 88 (0.4) | 2 (0.2) | 0.54 (0.13–0.13) | 0.397 |
30 | 9V | 81 | 80 (0.4) | 1 (0.1) | 0.31 (0.04–2.25) | 0.245 |
31 | 23F | 60 | 57 (0.3) | 3 (0.3) | 1.24 (0.38–4.08) | 0.722 |
32 | 18C | 55 | 51 (0.2) | 4 (0.4) | 1.23 (0.43–3.52) | 0.701 |
33 |
21 |
51 |
47 (0.2) |
4 (0.4) |
0.8 (0.28–2.3) |
0.683 |
*Values were adjusted for age and year of diagnosis. Only serotypes responsible for >50 cases of invasive pneumococcal disease were included. Serotypes of decreased odds (decreased aORs with significant p values) are indicated in light gray, and serotypes of increased odds (increased aORs and significant p values) are indicated in dark gray. aOR, adjusted odds ratio. †Because of multiple comparisons, a p value of <0.01 was considered significant. |
Page created: August 20, 2019
Page updated: August 20, 2019
Page reviewed: August 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.